Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Greg Rich who wrote (2455)	2/6/1999 12:03:00 AM
From: Abuckatatime	Read Replies (3) \| Respond to of 4676

Crooke did mention in the January stock-line.com interview that, and I'm paraphrasing, that while the company had cash in the bank sufficient to get the job done, that they might turn to the equity market sometime in the near future to raise additional cash. We didn't have long to wait. IMO, Crooke, in the interview, was optimistic about the future, stating that the "bulk of the technology risk was behind us", and that all drugs in the clinical pipeline were showing efficacy without limiting side-effects. He described 2302 as having remarkable positive effects with no side effects and no patient withdrawls. May the $50 mil from this offering help bring 2302, 3521, 5132, and the others successfully to market. That's the payoff. A revenue stream from anti-virals, anti-inflammatories, anti-Ca's, drug discovery and target validation collaborations, etc., that proves that the $50 mil worth of dilution was money well spent.